• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定 PI3K-AKT 通路相关基因并构建 ccRCC 的预后预测模型。

Identification of PI3K-AKT Pathway-Related Genes and Construction of Prognostic Prediction Model for ccRCC.

机构信息

Department of Urinary Surgery, Huaihe Hospital of Henan University, Kaifeng, China.

Department of Thoracic and Cardiovascular Surgery, Huaihe Hospital of Henan University, Kaifeng, China.

出版信息

Cancer Rep (Hoboken). 2024 Sep;7(9):e70010. doi: 10.1002/cnr2.70010.

DOI:10.1002/cnr2.70010
PMID:39233640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11375326/
Abstract

BACKGROUND

Clear cell renal cell carcinoma (ccRCC), the predominate histological type of renal cell carcinoma (RCC), has been extensively studied, with poor prognosis as the stage increases. Research findings consistently indicated that the PI3K-Akt pathway is commonly dysregulated across various cancer types, including ccRCC. Targeting the PI3K-Akt pathway held promise as a potential therapeutic approach for treating ccRCC. Development and validation of PI3K-Akt pathway-related genes related biomarkers can enhance healthcare management of patients with ccRCC.

PURPOSE

This study aimed to identify the key genes in the PI3K-Akt pathway associated with the diagnosis and prognosis of CCRCC using data mining from the Cancer Genome Atlas (TCGA) and Gene Expression Synthesis (GEO) datasets.

METHODS

The purpose of this study is to use bioinformatics methods to screen data sets and clinicopathological characteristics associated with ccRCC patients. The exhibited significantly differential expressed genes (DEGs) associated with the PI3K-Akt pathway were examined by KEGG. In addition, Kaplan-Meier (KM) analysis used to estimate the survival function of the differential genes by using the UALCAN database and graphPad Prism 9.0. And exploring the association between the expression levels of the selected genes and the survival status and time of patients with ccRCC based on SPSS22.0. Finally, a multigene prognostic model was constructed to assess the prognostic risk of ccRCC patients.

RESULTS

A total of 911 genes with common highly expressed were selected based on the GEO and TCGA databases. According to the KEGG pathway analysis, there were 42 genes enriched in PI3K-Akt signalling pathway. And seven of highly expressed genes were linked to a poor prognosis in ccRCC. And a multigene prognostic model was established based on IL2RG, EFNA3, and MTCP1 synergistic expression might be utilized to predict the survival of ccRCC patients.

CONCLUSIONS

Three PI3K-Akt pathway-related genes may be helpful to identify the prognosis and molecular characteristics of ccRCC patients and to improve therapeutic regimens, and these risk characteristics might be further applied in the clinic.

摘要

背景

透明细胞肾细胞癌(ccRCC)是肾细胞癌(RCC)的主要组织学类型,随着分期的增加,其预后较差。研究结果一致表明,PI3K-Akt 通路在包括 ccRCC 在内的各种癌症类型中经常失调。靶向 PI3K-Akt 通路有望成为治疗 ccRCC 的一种潜在治疗方法。开发和验证与 PI3K-Akt 通路相关的基因相关生物标志物可以增强对 ccRCC 患者的医疗保健管理。

目的

本研究旨在使用癌症基因组图谱(TCGA)和基因表达综合(GEO)数据集的数据挖掘,鉴定与 ccRCC 诊断和预后相关的 PI3K-Akt 通路中的关键基因。

方法

本研究旨在使用生物信息学方法筛选与 ccRCC 患者相关的数据组和临床病理特征。通过 KEGG 检查与 PI3K-Akt 通路相关的表现出显著差异表达基因(DEGs)。此外,使用 UALCAN 数据库和 graphPad Prism 9.0 进行 Kaplan-Meier(KM)分析,以估计差异基因的生存功能。并基于 SPSS22.0 探索所选基因的表达水平与 ccRCC 患者的生存状况和时间之间的关系。最后,构建多基因预后模型,以评估 ccRCC 患者的预后风险。

结果

基于 GEO 和 TCGA 数据库,共选择了 911 个具有共同高表达的基因。根据 KEGG 通路分析,有 42 个基因富集在 PI3K-Akt 信号通路中。并且,有 7 个高表达基因与 ccRCC 的不良预后相关。基于 IL2RG、EFNA3 和 MTCP1 的协同表达建立了一个多基因预后模型,可能用于预测 ccRCC 患者的生存。

结论

三个 PI3K-Akt 通路相关基因可能有助于识别 ccRCC 患者的预后和分子特征,并改善治疗方案,这些风险特征可能进一步应用于临床。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/23f6bd5b4fa4/CNR2-7-e70010-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/f120f76f450b/CNR2-7-e70010-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/208bead633ba/CNR2-7-e70010-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/4774867f1c62/CNR2-7-e70010-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/7d9d3106a5f2/CNR2-7-e70010-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/fc34d344168f/CNR2-7-e70010-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/e13d037ced6e/CNR2-7-e70010-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/23f6bd5b4fa4/CNR2-7-e70010-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/f120f76f450b/CNR2-7-e70010-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/208bead633ba/CNR2-7-e70010-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/4774867f1c62/CNR2-7-e70010-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/7d9d3106a5f2/CNR2-7-e70010-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/fc34d344168f/CNR2-7-e70010-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/e13d037ced6e/CNR2-7-e70010-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e1e/11375326/23f6bd5b4fa4/CNR2-7-e70010-g001.jpg

相似文献

1
Identification of PI3K-AKT Pathway-Related Genes and Construction of Prognostic Prediction Model for ccRCC.鉴定 PI3K-AKT 通路相关基因并构建 ccRCC 的预后预测模型。
Cancer Rep (Hoboken). 2024 Sep;7(9):e70010. doi: 10.1002/cnr2.70010.
2
PLAUR facilitates the progression of clear cell renal cell carcinoma by activating the PI3K/AKT/mTOR signaling pathway.PLAUR 通过激活 PI3K/AKT/mTOR 信号通路促进肾透明细胞癌的进展。
PeerJ. 2024 Jun 27;12:e17555. doi: 10.7717/peerj.17555. eCollection 2024.
3
TAGLN2 Promotes the Proliferation, Migration, Invasion, and EMT of Clear Cell Renal Cell Carcinoma Through the PI3K/Akt Signaling Pathway.TAGLN2 通过 PI3K/Akt 信号通路促进透明细胞肾细胞癌的增殖、迁移、侵袭和 EMT。
Biochem Genet. 2023 Aug;61(4):1265-1281. doi: 10.1007/s10528-022-10319-z. Epub 2022 Dec 22.
4
Activation of PI3K is associated with reduced survival in renal cell carcinoma.PI3K的激活与肾细胞癌患者生存率降低相关。
Urol Int. 2008;80(4):372-7. doi: 10.1159/000132694. Epub 2008 Jun 27.
5
Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.通过转录组学鉴定透明细胞肾细胞癌(ccRCC)的预后生物标志物。
Ann Clin Lab Sci. 2021 Sep;51(5):597-608.
6
FABP5 regulates the proliferation of clear cell renal cell carcinoma cells via the PI3K/AKT signaling pathway.脂肪细胞型脂肪酸结合蛋白 5 通过 PI3K/AKT 信号通路调节肾透明细胞癌细胞的增殖。
Int J Oncol. 2019 Apr;54(4):1221-1232. doi: 10.3892/ijo.2019.4721. Epub 2019 Feb 22.
7
ERBB2 is a potential diagnostic and prognostic biomarker in renal clear cell carcinoma.ERBB2 是肾透明细胞癌潜在的诊断和预后生物标志物。
Sci Rep. 2024 Oct 1;14(1):22775. doi: 10.1038/s41598-024-73574-7.
8
Exosomal microRNA-15a from ACHN cells aggravates clear cell renal cell carcinoma via the BTG2/PI3K/AKT axis.ACHN 细胞来源的外泌体 microRNA-15a 通过 BTG2/PI3K/AKT 轴加重肾透明细胞癌。
Kaohsiung J Med Sci. 2021 Nov;37(11):973-982. doi: 10.1002/kjm2.12428. Epub 2021 Aug 1.
9
A four-gene signature predicts survival in clear-cell renal-cell carcinoma.一种四基因特征可预测透明细胞肾细胞癌的生存率。
Oncotarget. 2016 Dec 13;7(50):82712-82726. doi: 10.18632/oncotarget.12631.
10
MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.微小RNA-194是透明细胞肾细胞癌预后良好的标志物。
Cancer Med. 2016 Apr;5(4):656-64. doi: 10.1002/cam4.631. Epub 2016 Feb 10.

引用本文的文献

1
Exploring LAT-derived miRNAs as regulatory agents of EphrinA3 in glioblastoma multiforme.探索源自LAT的微小RNA作为多形性胶质母细胞瘤中EphrinA3的调节因子。
Biochem Biophys Rep. 2025 Jul 6;43:102132. doi: 10.1016/j.bbrep.2025.102132. eCollection 2025 Sep.
2
The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression.7-甲基鸟苷(m7G)甲基化的METTL1作为透明细胞肾细胞癌进展的潜在生物标志物。
Transl Oncol. 2025 Jan;51:102202. doi: 10.1016/j.tranon.2024.102202. Epub 2024 Nov 20.

本文引用的文献

1
PLAUR facilitates the progression of clear cell renal cell carcinoma by activating the PI3K/AKT/mTOR signaling pathway.PLAUR 通过激活 PI3K/AKT/mTOR 信号通路促进肾透明细胞癌的进展。
PeerJ. 2024 Jun 27;12:e17555. doi: 10.7717/peerj.17555. eCollection 2024.
2
Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform.Sangerbox:一个全面的、用户交互友好的临床生物信息学分析平台。
Imeta. 2022 Jul 8;1(3):e36. doi: 10.1002/imt2.36. eCollection 2022 Sep.
3
IFI16 promotes the progression of clear cell renal cell carcinoma through the IL6/PI3K/AKT axis.
IFI16 通过 IL6/PI3K/AKT 轴促进肾透明细胞癌的进展。
J Transl Med. 2024 Jun 3;22(1):533. doi: 10.1186/s12967-024-05354-w.
4
Unlocking Precision Medicine: Liquid Biopsy Advancements in Renal Cancer Detection and Monitoring.解锁精准医学:液体活检在肾癌检测和监测中的进展。
Int J Mol Sci. 2024 Mar 30;25(7):3867. doi: 10.3390/ijms25073867.
5
PHF8-GLUL axis in lipid deposition and tumor growth of clear cell renal cell carcinoma.PHF8-GLUL 轴在透明细胞肾细胞癌的脂质沉积和肿瘤生长中的作用。
Sci Adv. 2023 Aug 2;9(31):eadf3566. doi: 10.1126/sciadv.adf3566.
6
PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells.PI3K/AKT 信号通路作为肿瘤细胞顺铂反应的关键调节因子。
Oncol Res. 2022 Aug 31;29(4):235-250. doi: 10.32604/or.2022.025323. eCollection 2021.
7
A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma.一项转移性肾细胞癌患者中舒尼替尼和替西罗莫司交替治疗的 II 期研究。
Cancer Med. 2023 Jun;12(12):13100-13110. doi: 10.1002/cam4.5990. Epub 2023 May 6.
8
Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.细胞减灭性肾切除术和转移性肾细胞癌:现状和未来展望。
Medicina (Kaunas). 2023 Apr 15;59(4):767. doi: 10.3390/medicina59040767.
9
Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma.目前透明细胞肾细胞癌中基因组生物标志物的研究现状。
Eur Urol. 2023 Aug;84(2):166-175. doi: 10.1016/j.eururo.2023.04.003. Epub 2023 Apr 19.
10
ZDHHC2-Mediated AGK Palmitoylation Activates AKT-mTOR Signaling to Reduce Sunitinib Sensitivity in Renal Cell Carcinoma.ZDHHC2 介导的 AGK 棕榈酰化激活 AKT-mTOR 信号通路,降低肾细胞癌对舒尼替尼的敏感性。
Cancer Res. 2023 Jun 15;83(12):2034-2051. doi: 10.1158/0008-5472.CAN-22-3105.